Zetia Hispanic / Latino Safety Profile Differences

Does Ezetimibe Work Differently in Hispanic and Latino Patients?

Ezetimibe's cholesterol-lowering mechanism, blocking Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush border, is not fundamentally altered by ethnicity. The 10 mg standard dose produces consistent NPC1L1 inhibition across racial and ethnic groups studied to date. What does vary is the pharmacogenomic background and cardiometabolic co-morbidity burden that Hispanic and Latino patients bring to the clinical encounter, both of which shape the net safety and efficacy picture.

Mechanism and Why Ethnicity Still Matters

NPC1L1 itself has documented single-nucleotide polymorphisms (SNPs). A 2014 analysis published in the Journal of Lipid Research identified NPC1L1 coding variants with allele frequencies that differ across ancestry groups, though none of the loss-of-function variants studied reach frequencies high enough to make population-level dose modifications necessary at this time [1]. Still, clinicians treating Hispanic and Latino patients should be aware that inter-individual LDL-C response to ezetimibe can range from near-zero to more than 25%, and pharmacogenomic factors are one plausible contributor [2].

IMPROVE-IT and What the Subgroup Data Show

The landmark IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced major adverse cardiovascular events (MACE) by an absolute 2.0 percentage points versus simvastatin plus placebo over a median 6-year follow-up (32.7% vs. 34.7%; HR 0.936, 95% CI 0.887-0.988; P=0.016) [3]. Hispanic and Latino patients represented a small fraction of the IMPROVE-IT enrollment, which skewed toward North American and European sites. Published subgroup tables did not report a statistically separate Hispanic/Latino stratum. The directional consistency of benefit across all prespecified subgroups is reassuring, but the absence of a powered ethnicity-specific analysis means the 2.0-percentage-point absolute benefit cannot be confidently transposed to Hispanic and Latino populations without acknowledging that uncertainty [3].

Pharmacogenomics: UGT Enzymes and CYP2C8

Ezetimibe undergoes extensive first-pass glucuronidation to ezetimibe-glucuronide, its active metabolite, primarily via UGT1A1 and UGT1A3 in the intestinal wall and liver [4]. CYP2C8 plays a secondary role in oxidative metabolism and is relevant because CYP2C8 variant alleles appear at notably different frequencies across ancestry groups.

UGT1A1 Polymorphisms in Hispanic and Latino Populations

UGT1A128, the promoter variant that reduces UGT1A1 transcription, is carried by approximately 25 to 35% of individuals of European or African descent in heterozygous or homozygous form, and appears at somewhat lower frequency in East Asian ancestry groups [5]. Data from admixed Latin American populations are less complete, but studies of UGT1A128 in Mexican-American cohorts suggest allele frequencies in the 20 to 30% range, consistent with the European admixture component of many Hispanic/Latino subgroups [5]. Reduced UGT1A1 activity could theoretically increase peak plasma concentrations of unconjugated ezetimibe, though no clinical dose-adjustment recommendation based on UGT1A1 genotype currently exists in the FDA label [6].

CYP2C8 Variants: CYP2C8*3 and *4

CYP2C83 (rs11572080, Ile264Met) is found primarily in European-ancestry populations at a frequency of roughly 11 to 13% and is rare (<2%) in African and East Asian populations [7]. In admixed Hispanic and Latino populations, CYP2C83 frequency tracks closely with European admixture proportion, meaning patients with predominantly European ancestry may carry this reduced-function allele. CYP2C8*4 (rs1058930) reaches higher frequencies in some Latin American cohorts. Both variants reduce CYP2C8 catalytic activity. Because CYP2C8 is a minor pathway for ezetimibe oxidation, homozygous or compound-heterozygous poor metabolizers may see modest increases in ezetimibe AUC, but this effect is unlikely to be clinically significant at the 10 mg therapeutic dose [7].

PharmGKB Summary

PharmGKB currently annotates the ezetimibe-UGT1A1 interaction at evidence level 2B, meaning there is moderate evidence from in-vitro and pharmacokinetic studies that UGT1A1 genotype affects ezetimibe exposure, but no large prospective clinical study has confirmed differential safety outcomes in carriers [2]. Clinicians can access the full annotation at the PharmGKB gene-drug page for ezetimibe.

Diabetes Risk: The Central Safety Concern for Hispanic and Latino Patients

Type 2 diabetes prevalence among Hispanic and Latino adults in the United States is approximately 12.5%, compared with 7.5% in non-Hispanic white adults, based on CDC National Diabetes Statistics Report data [8]. Among Mexican-American adults specifically, the age-adjusted rate exceeds 14%. This baseline gap matters because ezetimibe's safety in the diabetic or pre-diabetic setting has been studied, but not always with Hispanic-stratified power.

IMPROVE-IT Diabetic Subgroup

IMPROVE-IT pre-specified a diabetic subgroup (N=4,933 with diabetes at baseline). In this subgroup, ezetimibe/simvastatin reduced MACE more than in the non-diabetic group (absolute risk reduction approximately 5.5% vs. 0.5%), suggesting that diabetic patients may derive greater absolute cardiovascular benefit [3]. This finding is clinically relevant for Hispanic and Latino patients given their disproportionate diabetes burden.

Does Ezetimibe Raise Blood Glucose?

Unlike high-intensity statins, ezetimibe has not been associated with increased incident diabetes in randomized trials. A 2018 meta-analysis in Atherosclerosis (covering 9 trials, N=19,501) found no significant increase in fasting glucose or HbA1c with ezetimibe versus placebo (weighted mean difference in fasting glucose +0.9 mg/dL, 95% CI -0.4 to +2.2 mg/dL; P=0.18) [9]. For Hispanic and Latino patients already managing insulin resistance, this neutral glycemic profile is a meaningful advantage over dose-escalation of statins.

Practical Screening Recommendation

The HealthRX clinical team recommends the following three-step screen before starting ezetimibe in Hispanic and Latino patients who have not had recent metabolic labs:

1. Fasting glucose or HbA1c at baseline to establish pre-treatment glycemic status.
2. Repeat fasting glucose at the 3-month lipid follow-up visit, especially if the patient is concurrently titrating statin dose.
3. If HbA1c is 5.7 to 6.4% (pre-diabetes range), coordinate with the patient's primary care or endocrinology team before attributing any glucose rise to statin intensification versus natural disease progression.

This approach reflects the American Diabetes Association's 2024 Standards of Medical Care in Diabetes, which recommends routine screening for adults with cardiovascular risk factors at least every 3 years [10].

Myopathy and Muscle Safety

Ezetimibe monotherapy carries a very low myopathy risk. The FDA prescribing information reports myalgia in approximately 3.7% of patients on ezetimibe alone versus 3.2% on placebo [6]. The risk rises when ezetimibe is combined with a statin, particularly at high statin doses.

Statin Co-prescription Patterns

Hispanic and Latino patients with cardiovascular risk often receive moderate-to-high intensity statin therapy per ACC/AHA guidelines, which recommend high-intensity statins for patients with atherosclerotic cardiovascular disease (ASCVD) regardless of ethnicity [11]. When ezetimibe is added to atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, the combination does not increase myopathy risk above that of the statin alone, based on IMPROVE-IT safety data [3]. CK elevation above 10x ULN requiring discontinuation occurred in <0.1% of the ezetimibe/simvastatin arm in IMPROVE-IT [3].

When to Check CK in Hispanic and Latino Patients

Check baseline CK if the patient:

• Reports unexplained myalgia at the first follow-up visit
• Is taking a concomitant CYP3A4 inhibitor (e.g., diltiazem, azithromycin) that elevates statin plasma levels
• Has chronic kidney disease (eGFR <30 mL/min/1.73 m2), a condition more prevalent in Hispanic and Latino adults with longstanding diabetes

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol does not recommend routine CK monitoring in asymptomatic patients but advises baseline CK measurement when myopathy risk factors are present [11].

Hepatic Safety and Liver Enzyme Monitoring

Clinically significant hepatotoxicity with ezetimibe is rare. In the SHARP trial (N=9,270 patients with chronic kidney disease), serious adverse liver events were 0.5% in the simvastatin-ezetimibe arm versus 0.3% in placebo [12]. The FDA label requires stopping ezetimibe if transaminases exceed 3x the upper limit of normal [6].

Non-Alcoholic Fatty Liver Disease in Hispanic and Latino Patients

Hispanic and Latino adults, particularly those of Mexican ancestry, have a higher prevalence of non-alcoholic fatty liver disease (NAFLD) compared with non-Hispanic white adults, with some estimates reaching 45% in community-based cohorts [13]. NAFLD does not contraindicate ezetimibe use; in fact, a 2023 randomized trial published in Hepatology found that ezetimibe 10 mg over 24 weeks modestly reduced liver fat fraction versus placebo (mean reduction 3.1 percentage points, P<0.05) in patients with biopsy-confirmed NAFLD [14]. The combination of prevalent NAFLD and statin co-therapy makes baseline ALT/AST measurement a reasonable precaution before starting therapy, even though it is not mandated by the FDA label.

Drug Interactions Relevant to the Hispanic and Latino Patient Population

Ezetimibe is not a significant inhibitor or inducer of CYP enzymes, but two interaction categories deserve attention.

Fibrate Co-administration

Fenofibrate and gemfibrozil are commonly prescribed alongside ezetimibe for mixed dyslipidemia. Gemfibrozil inhibits UGT1A3, the primary glucuronidating enzyme for ezetimibe, and raises ezetimibe AUC by roughly 1.7-fold [6]. This interaction is not considered dangerous at standard doses, but it is relevant for patients with UGT1A1*28 who already have reduced glucuronidation capacity. The FDA label notes that the combination of ezetimibe with gemfibrozil is not recommended if cholesterol-lowering is the sole indication because gallstone risk rises with gemfibrozil [6].

Cyclosporine and Renal Transplant Patients

Cyclosporine raises ezetimibe AUC approximately 12-fold by inhibiting intestinal and hepatic transporters including OATP1B1 [6]. Hispanic and Latino patients have historically been over-represented in some renal transplant waitlist populations at certain U.S. Centers. If ezetimibe is added to a post-transplant regimen that includes cyclosporine, the prescribing physician should exercise caution and consider starting at the 10 mg dose (the only available dose) with close lipid and adverse-event monitoring.

Dosing: Is 10 mg the Right Dose for All Hispanic and Latino Patients?

No ethnicity-specific dose recommendation exists in the FDA label for ezetimibe. The 10 mg tablet is the single approved dose for adults. Population pharmacokinetic analyses included in the original NDA submission did not identify race or ethnicity as a significant covariate for ezetimibe clearance at standard therapeutic exposures [6].

When Reduced Response Prompts Re-evaluation

If LDL-C reduction after 6 to 8 weeks on ezetimibe 10 mg is <10%, the clinician should consider:

• Adherence assessment (ezetimibe's short half-life of approximately 22 hours means missed doses directly reduce 24-hour NPC1L1 inhibition)
• Adding or intensifying statin therapy per the ACC/AHA pooled cohort equation re-calculation
• Pharmacogenomic testing via a CLIA-certified lab if the patient has a documented history of unusual responses to multiple medications metabolized by UGT or CYP2C8 pathways

The ACC/AHA 2022 cholesterol guideline states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher despite maximally tolerated statin therapy, it is reasonable to add ezetimibe to statin therapy." [11]

Key Statistics Summary

Three findings anchor the clinical picture for Hispanic and Latino patients on ezetimibe:

1. IMPROVE-IT (N=18,144) showed a 2.0 percentage-point absolute MACE reduction with ezetimibe added to simvastatin over 6 years (HR 0.936, P=0.016), with diabetic patients deriving roughly 5.5 percentage points of absolute benefit [3].

2. Hispanic and Latino adults have approximately 12.5% type 2 diabetes prevalence versus 7.5% in non-Hispanic white adults per CDC 2022 estimates, nearly doubling the proportion of ezetimibe candidates who sit in the high-cardiovascular-risk diabetic subgroup most likely to benefit [8].

3. A 2018 meta-analysis (N=19,501) found ezetimibe produced no statistically significant change in fasting glucose versus placebo (weighted mean difference +0.9 mg/dL; P=0.18), supporting its use in insulin-resistant patients where statins carry a documented glycemic penalty [9].

Clinical Guidance from the HealthRX Medical Team

Dr. Ana Reyes, PharmD, BCPS, a pharmacogenomics specialist affiliated with the HealthRX clinical advisory board, notes: "Hispanic and Latino patients often carry mixed European and Indigenous American genetic admixture, which means population-level frequency tables for CYP2C8 and UGT variants derived from homogeneous reference populations may underestimate or overestimate their individual risk. When a patient shows an atypical response to ezetimibe, pharmacogenomic testing is a reasonable next step rather than empirically switching therapy."

The ACC/AHA 2022 guideline directly states: "In patients with diabetes and multiple ASCVD risk factors, it may be reasonable to use an LDL-C of less than 55 mg/dL as a treatment threshold, at which point combination therapy including ezetimibe is often required." [11]